GPP
TVRD

Great Point Partners’s Tvardi Therapeutics TVRD Stock Holding History

Great Point Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,374
Closed -$761K – 44
2017
Q2 		$761K Buy
+1,374
New +$872K 0.14% 36
2014
Q4 		– Sell
-1,314
Closed -$397K – 36
2014
Q3 		$397K Sell
1,314
-4,248
-76% -$1.74M 0.17% 36
2014
Q2 		$3.41M Buy
5,562
+616
+12% +$332K 1.52% 23
2014
Q1 		$3.31M Buy
+4,946
New +$2.93M 1.73% 21

Other funds holding TVRD

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Great Point Partners's TVRD Position: Q3 2017 in Review

Great Point Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 1,374 shares — an estimated $761K sold.

Great Point Partners first reported a position in TVRD in Q1 2014 and held it in 4 quarters. The position peaked at $3.41M in Q2 2014. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • Great Point Partners reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Great Point Partners sold 1,374 Tvardi Therapeutics shares in Q3 2017, an estimated $761K.
  • Great Point Partners first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 4 quarters.
  • Great Point Partners's Tvardi Therapeutics position peaked at $3.41M in Q2 2014.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Great Point Partners's 13F filing for Q3 2017, filed 14 Nov 2017.